Celldex Therapeutics, Inc. (CLDX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$28.27-5.55%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CLDX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 1.5 | 7.0 | 6.9 | 2.4 | 4.7 | 7.4 | 3.6 | 9.5 | 12.7 | 6.8 | 5.5 | 3.6 | 4.1 | 11.2 | 9.3 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 12.7 | 6.8 | 5.5 | 3.6 | 4.1 | 11.2 | 9.3 |
| Cost of Revenues | — | 0.2 | 0.2 | 0.3 | 0.1 | 0.1 | 0.2 | 0.1 | 0.7 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 278.8 | 245.1 | 163.6 | 118.0 | 82.3 | 53.3 | 42.5 | 42.7 | 66.4 | 96.2 | 102.7 | 100.2 | 104.4 | 67.4 | 47.4 | 32.4 |
| Operating Income | (325.8) | (287.4) | (195.1) | (154.5) | (115.2) | (71.2) | (63.4) | (55.0) | (156.4) | (121.5) | (132.9) | (129.5) | (122.4) | (81.4) | (58.1) | (43.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | 0.9 | 0.9 | 0.9 | 1.6 | 1.8 |
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.4 |
| Asset Writedown | — | — | — | — | — | — | — | — | 18.7 | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | (258.8) | (157.9) | (141.4) | (112.3) | (70.7) | (60.9) | (50.9) | (151.9) | (117.3) | — | — | — | — | — | (44.8) |
| Income Tax Expense | — | — | — | 0.0 | — | (0.2) | (1.2) | (0.8) | (0.8) | (24.3) | — | — | — | 0.0 | 0.0 | (0.5) |
| Net Income | ||||||||||||||||
| Net Income | (300.5) | (258.8) | (157.9) | (141.4) | (112.3) | (70.5) | (59.8) | (50.9) | (151.2) | (93.0) | (128.5) | (127.2) | (118.1) | (81.6) | (59.1) | (44.8) |
| Per Share | ||||||||||||||||
| Basic EPS | (3.86) | (3.90) | (2.45) | (2.92) | (2.40) | (1.64) | (2.02) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (3.86) | (3.90) | (2.45) | (2.92) | (2.40) | (1.64) | (2.02) | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 77.8 | 66.4 | 0.1 | 48.4 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | 39.5 |
| Diluted Weighted Avg Shares | 77.8 | 66.4 | 0.1 | 48.4 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | 39.5 |
| Supplemental | ||||||||||||||||
| EBITDA | — | (284.0) | (191.9) | (151.5) | (112.3) | (68.2) | (59.4) | (50.2) | (152.9) | (117.1) | (129.8) | (126.5) | (120.0) | (79.5) | (56.0) | (41.2) |
| EBIT | (325.8) | (287.4) | (195.1) | (154.5) | (115.2) | (71.2) | (63.4) | (55.0) | (156.4) | (121.5) | (132.9) | (129.5) | (122.4) | (81.4) | (58.1) | (43.4) |
| Effective Tax Rate | — | — | — | 0.0% | — | 0.3% | 1.9% | 1.5% | 0.5% | 20.7% | — | — | — | — | — | 1.2% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.